Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.

Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells.

Cancer Lett. 2013 Jan 19;

Authors: Nishi T, Iwasaki K, Ohashi N, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kobayashi T, Kodera Y

Abstract
We studied the effect of everolimus, an inhibitor of the mammalian target of rapamycin (mTOR) on human gastric cancer cell lines. Cell proliferation in 3 of 8 cell lines was effectively inhibited by everolimus. Basal phosphorylation level of 4E-BP1 (T37/46, T70) was significantly higher in everolimus-sensitive cells than in everolimus-resistant cells. In subcutaneous xenograft model, immunohistochemistry analysis revealed that everolimus-sensitive cells expressed high levels of phospho-4E-BP1 (T37/46). In conclusion, phosphorylation of 4E-BP1 may be a predictive biomarker of everolimus sensitivity in gastric cancer.

PMID: 23340172 [PubMed - as supplied by publisher]

coxinhibitors c-met inhibitors zm-447439